SCHEMBL4257410

SCHEMBL4257410

NC(=O)c1oc2cc(Cl)ccc2c1N

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.77
ALDH1A1 P00352 5/20 0.77
HPGD P15428 4/20 0.77
HSD17B10 Q99714 2/20 0.77
MCL1 Q07820 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 2/20 0.47
USP2 O75604 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TTR P02766 2/20 0.45
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
AHR P35869 1/20 0.43
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851374 0.87 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL20535696 0.84 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL11126983 0.83 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL22006944 0.81 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL13699685 0.80 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL13699669 0.80 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL20535014 0.78 KDM4E (0.78) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL25240056 0.78 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL31015988 0.78 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL20535434 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615578-A1 CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2025-09-17 EP disclosed
EP-4615849-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2025-09-17 EP disclosed
CN-120202206-A Cyclic benzimidazole derivatives as cGAS inhibitors 勃林格殷格翰国际有限公司 2025-06-24 CN disclosed
US-20240208997-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 US disclosed
US-20240189315-A1 Cyclic Pyridine Derivatives as cGAS Inhibitors BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2024-06-13 US disclosed
WO-2024099908-A1 CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-16 WO disclosed
WO-2024099907-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-16 WO disclosed
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1710233-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE Kissei Pharmaceutical Co., Ltd. (JP) 2006-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE ADORA2A, ADORA2B, HTR1F KDM4E 4227/4885ALDH1A1 559/4885HPGD 3251/4885
US-20240208997-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS CGAS, STING1, IFNAR1 KDM4E 2028/4885ALDH1A1 815/4885HPGD 942/4885
US-20240189315-A1 Cyclic Pyridine Derivatives as cGAS Inhibitors CGAS, STING1, IRF3 KDM4E 1598/4885ALDH1A1 1257/4885HPGD 417/4885
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS KDM4E 3126/4885ALDH1A1 1112/4885HPGD 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.